Skip to main content

Coronavirus (COVID-19): Visitor Restrictions, Resources, and Updates

Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

Ustekinumab for Primary Sjogren's Syndrome

Research Question:
What is the safety and effect of the drug, ustekinumab, in patients with Primary Sjogren's Syndrome?

Basic Study Information

Purpose:
Ustekinumab is FDA approved for treatment of Psoriasis, Psoriatic Arthritis, and Crohn's disease, but it has not been previously used in the treatment of Primary Sjogren's Syndrome. Participants will complete 6 study visits over the course of 6 months. Subjects will receive an infusion of ustekinumab at the second visit and an injection of ustekinumab at the next 3 visits. Subjects will have assessments of their health at all visits.

Location: University of Rochester
Study Reference #: 3820

Lead Researcher (Principal Investigator)

Lead Researcher:  Ummara Shah

Study Contact Information

Study Coordinator: Alena Leger
Phone: (585) 275-1634
Email: alena_leger@urmc.rochester.edu

Additional Study Details

Number of Visits:  6 to 10
Parking:  Reimbursed
Reimbursement:  Yes

Learn More About These Conditions

More information about Sjogren's Syndrome

Return to Search